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 Poverty drives tuberculosis (TB) rates but the approach to 
TB control has been disproportionately biomedical. In 2015, 
the World Health Organization's  End TB Strategy explicitly 
identiﬁed the need to address the social determinants of TB 
through socio-economic interventions. However, evidence 
concerning poverty reduction and cost mitigation strategies 
is limited. The research described in this article, based on 
the 2016 Royal College of Physicians Linacre Lecture, aimed 
to address this knowledge gap. The research was divided 
into two phases: the ﬁrst phase was an analysis of a cohort 
study identifying TB-related costs of TB-affected households 
and creating a clinically relevant threshold above which 
those costs became catastrophic; the second was the design, 
implementation and evaluation of a household randomised 
controlled evaluation of socio-economic support to improve 
access to preventive therapy, increase TB cure, and mitigate 
the effects of catastrophic costs. The ﬁrst phase showed TB 
remains a disease of people living in poverty – ‘free’ TB care 
was unaffordable for impoverished TB-affected households 
and incurring catastrophic costs was associated with as 
many adverse TB treatment outcomes (including death, 
failure of treatment, lost to follow-up and TB recurrence) 
as multidrug resistant (MDR) TB. The second phase showed 
that, in TB-affected households receiving socio-economic 
support, household contacts were more likely to start and 
adhere to TB preventive therapy, TB patients were more 
likely to be cured and households were less likely to incur 
catastrophic costs. In impoverished Peruvian shantytowns, 
poverty remains inextricably linked with TB and incurring 
catastrophic costs predicted adverse TB treatment outcome. 
A novel socio-economic support intervention increased TB 
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preventive therapy uptake, improved TB treatment success 
and reduced catastrophic costs. The impact of the intervention 
on TB control is currently being evaluated by the Community 
Randomized Evaluation of a Socio-economic Intervention to 
Prevent TB (CRESIPT) study. 
 KEYWORDS :  catastrophic costs ,  conditional cash transfers , 
 End TB Strategy ,  poverty ,  social determinants ,  social protection , 
 socio-economic support ,  TB 
 Introduction 
 Over a century ago, Virchow recognised that tuberculosis (TB) 
was a social disease. 1 Since then, Koch's discovery of the bacillus 
and the discovery of streptomycin and other antimicrobials 
provided humankind with a means to both diagnose and 
treat TB. Yet TB rates in Europe fell during the industrial 
revolution, prior to either the discovery of the TB bacillus or TB 
antimicrobial therapy. This decrease was predominantly caused 
by changes in social determinants such as improved living 
conditions  2,3 and nutrition. 4,5 
 TB rates worldwide are declining slowly and remain 
unacceptably high: a third of the world's population is 
estimated to be infected with TB and 1.5 million people died 
of TB in 2014, the majority of whom were impoverished 
people living in resource-constrained settings. 6 Thus, TB 
remains a social disease inextricably linked in a vicious cycle 
with poverty. Specifically, being poor continues to increase 
the risk of acquiring TB infection and disease 7–9 and having 
TB disease worsens poverty in TB-affected households. 10–12 
However, the global TB control and research strategy has been 
disproportionately focused on a biomedical rather than socio-
economic response to the epidemic. Despite helping to cure 
millions of people of TB disease, 8 a biomedical-only response 
to TB will not be enough to eradicate TB this century. To end 
TB globally, a more holistic approach, which continues to 
incorporate biomedical responses and also addresses the broader 
socio-economic determinants of this disease, is required. 11 , 13–16 
 Addressing the social determinants of TB is not a new 
concept. Almost 100 years ago, the Papworth study (a socio-
medical experiment performed at the Papworth Village 
Settlement in England) showed that stable employment and 
adequate housing and nutrition for households of parents with 
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active TB disease decreased the incidence of TB infection and 
disease in their children. 2 Nevertheless, since the advent of the 
antibiotic era, such social and economic support interventions 
received less attention and the response to TB became focused 
almost solely on the biomedical. 
 In the 2015  End TB Strategy , the World Health Organization 
(WHO) cited mitigation of TB-related costs and provision 
of socio-economic support to TB-affected households 
as key pillars in the global response to TB for the first 
time. 16 However, rigorous evidence with which to guide 
society, policymakers and national TB programmes on the 
implementation of cost mitigation and TB-specific socio-
economic interventions (eg focused only on TB-affected 
people) remains extremely limited. 9,17,18 
 For over a decade, our research group ( www.ifhad.org ) has 
worked with TB-affected households in the shantytowns of 
Callao, Peru – an area in which approximately a third of the 
population live on less than $1.50 a day and that has pockets of 
gun crime and drug addiction. From 2007–11, we conducted an 
assessment of innovative socio-economic interventions against 
TB (ISIAT) in 16 shantytown communities of Callao. 15 The 
interventions had two dimensions: 
 1  education, community mobilisation and psychosocial support 
to increase uptake of TB care 
 2  food transfers, microcredit, microenterprise and vocational 
training to reduce poverty. 
 In a pre- versus post-intervention analysis, the intervention 
increased preventive chemotherapy in household contacts, and 
HIV testing and TB treatment completion in TB patients. 15 
 Extending the ISIAT project findings, the IFHAD team 
performed a randomised controlled evaluation of a socio-
economic support intervention incorporating conditional 
cash transfers in 32 shantytown communities of Callao. The 
research was carried out in two phases: phase 1 aimed to 
measure and define catastrophic costs of accessing ‘free’ TB 
care and their impact on TB treatment outcomes; and phase 2 
aimed to design, implement and evaluate the TB-specific socio-
economic intervention, including conditional cash transfers to 
enhance access to TB preventive therapy, improve TB treatment 
outcomes and mitigate the effects of catastrophic costs in 
supported TB-affected households. This article summarises 
the findings of this research as presented during the Linacre 
Lecture at the Royal College of Physician's Advanced Medicine 
conference in January 2016. 
 Phase 1: deﬁning catastrophic costs and comparing 
their importance for adverse tuberculosis outcome 
with multidrug resistance 
 While many countries aim to offer ‘free’ TB treatment to 
their patients, this may only cover some diagnostic tests and 
anti-mycobacterial medications. Patients and their households 
may incur hidden TB-related costs such as direct ‘out-of-
pocket’ expenses (including transport, symptom-relieving 
medicines and additional food) or indirect expenses associated 
with lost income. 19–22 A goal of the WHO's  End TB Strategy 
mandates eradicating catastrophic costs for TB-affected 
families by 2020. 14 However, hidden TB-related costs remain 
understudied and a unifying definition of catastrophic costs is 
awaited. 14 , 23–26 
 Methods 
 We conducted a prospective cohort study of 876 TB patients 
(11% of whom had MDR TB) that used repeated TB patient 
interviews (at treatment initiation, then at 2, 4, 8, 12, 16, 20 and 
24 weeks of treatment) to quantify changes in income and hidden 
TB-related costs prior to and throughout treatment. The socio-
economic section of the questionnaire used can be accessed at 
 https://spiral.imperial.ac.uk/handle/10044/1/31465 or in a 
related publication. 11 This better characterised TB-related costs, 
their association with adverse TB outcome and contributed to an 
evidence-based definition of catastrophic costs that is relevant 
both financially and clinically (eg relating to TB patients’ and 
their contacts’ health outcomes). 
 The study took place in 32 shantytown communities in Callao, 
Peru, with an estimated population of one million people. The 
annual TB notification rate across these communities was 206 
new cases per 100,000 people between 2011 and 2013, greater 
than the national rate of 95 per 100,000 people. 
 Measured costs included direct expenses and lost income. 
Direct expenses included direct medical expenses (medical 
examinations and prescribed medicines) and direct non-
medical expenses (natural non-prescribed remedies, TB 
care-related transport, extra food and other miscellaneous 
expenses). With regard to direct medical expenses, while 
sputum sample testing and chest radiograph for diagnosis of TB 
and anti-mycobacterial therapy for treatment of TB is provided 
free by the Peruvian national TB control programme, patients 
may have multiple consultations prior to diagnosis (eg seen 
with fever and cough but not tested for TB), for which they may 
incur costs. Lost income was the income the patient estimated 
that the household lost because of TB illness or tuberculosis-
related time off work (such as attending clinics) since the 
previous interview. Poverty was measured using a composite 
household poverty index in arbitrary units derived by principal 
component analysis from 13 variables, as described. 15 A 
threshold for catastrophic costs was calculated by plotting the 
sensitivity, specificity and population attributable fraction 
for adverse TB outcome against total household costs as a 
proportion of annual household income. Adverse TB outcome 
was defined as death, loss to follow-up or treatment failure 
during therapy, or recurrence within 2 years. 
 Results 
 Accessing TB care cost TB-affected households approximately 
2 months of their annual household income with half of the 
costs being incurred prior to the start of TB treatment and 
half consisting of lost income (Fig  1 ). In poorer households, 
costs were lower but constituted a higher proportion of the 
household's annual income: 27% (95% CI 20–43%) in the 
least poor houses versus 48% (95% CI 36–50%) in the poorest 
(Fig  2 ). 23% (166/725) of patients with a defined treatment 
outcome had an adverse outcome. Total costs ≥20% of 
household annual income was defined as catastrophic because 
this threshold was most strongly associated with adverse TB 
outcome. Catastrophic costs were incurred by 345 households 
(39%). Adverse treatment outcome was independently 
associated with MDR TB (odds ratio (OR)=8.4 (95% CI 
4.7–15), p<0.001) and catastrophic costs (OR=1.7 (95% CI 
1.1–2.6), p=0.01, Fig  3 ). The adjusted population attributable 
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 Fig 1.  Average lost income, 
constituent direct expenses and 
total expenses by treatment 
stage. n=876 
*Peruvian currency, 3 Soles = 1 US $. 
The numbers in parentheses 
represent percentage of total 
expenses. ‘Medical’ expenses are 
deﬁ ned as the sum of direct 
expenses for medicines and 
clinical exams; ‘non-medical’ 
expenses are deﬁ ned as the sum 
of direct expenses for natural 
remedies, TB care-related 
transport, extra food and other 
TB-related expenses. 
23/876 (2.6%) of the TB patient 
cohort had direct expenses of 0 
Peruvian soles and 14/876 (1.6%) 
had total expenses of 0 Peruvian 
soles and for analysis; these zero 
values were replaced by 0.5 
Peruvian soles per day (with the 
midpoint between zero and the 
lowest measured unit, one Sole). 
Reproduced with permission from 
Wingﬁ eld  et al . 11  
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 Fig 2.  Expenses and economic 
burden of tuberculosis illness 
across poverty terciles. A – total 
expenses as proportion of annual 
income; B –direct expenses. 
Reproduced with permission from 
Wingﬁ eld  et al . 11 
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fraction of adverse outcomes explained by catastrophic costs 
was 18% (95% CI 6.9–28%), similar to that of MDR TB (20% 
(95% CI 14–25%)). 
 Discussion 
 This study defined a novel, evidence-based threshold of 
total costs greater than 20% of annual household income 
as catastrophic for TB-affected households because it was 
associated with increased likelihood of adverse TB outcome, 
independent of MDR TB status. Analysis of the population 
attributable fraction also implied that almost a fifth of adverse 
TB outcomes could be averted by eliminating catastrophic costs 
from the study population, similar to MDR TB. In addition, as 
has been shown in other settings, 19–21 accessing free TB care was 
expensive for TB patients and the poorest households incurred 
the greatest costs as a proportion of their household income – 
typifying the ‘medical poverty trap’. 27,28 
 This study added a new dimension to the social protection 
TB literature by showing how catastrophic costs can also 
have significant clinical implications: loss of income and 
increasing hidden costs have previously been associated 
with poor treatment adherence and high dropout rates in 
TB patients  20,29,30 but their independent effect on long-
term TB outcome has not been previously characterised. 
We hypothesised that the relationship we found between 
catastrophic costs and adverse TB outcome may relate to 
a number of factors along the causal pathway from TB 
susceptibility to illness to recurrence, including inadequate 
nutrition due to lower food spending, more severe TB 
disease and barriers to cure because of the disproportionate 
hidden costs associated with adherence to and completion of 
treatment. 
 The findings of phase 1 of our research suggested that 
TB-related costs incurred by TB-affected households are not 
only financially but also clinically relevant – influencing TB 
treatment outcomes. Thus, TB control interventions must 
consider addressing TB as an infectious and socio-economic 
problem. The innovative catastrophic costs’ threshold was 
subsequently endorsed by WHO within their global tool to 
estimate country-specific TB-related and catastrophic costs of 
TB patients and their TB-affected households. The tool, which 
builds on the published ‘tool to estimate patients’ costs’ 27 and 
includes measurement of lost income in addition to direct out-
of-pocket expenses, is being piloted and rolled-out in sentinel 
countries from 2015 onwards, prior to being refined and 
implemented globally. 
 Phase 2: designing, implementing and evaluating a 
socio-economic intervention to mitigate the effects of 
catastrophic costs, enhance access to TB preventive 
therapy and improve TB treatment outcomes 
 Enhancing access to TB preventive therapy and treatment 
is likely to improve TB prevention and cure. 31–34 Alongside 
the existing biomedical approach, complementary strategies, 
including socio-economic support, are required to meet global 
TB control goals. 35–52 
 Social protection and socio-economic support interventions 
consist of policies and programmes designed to reduce poverty 
and vulnerability by improving people's capacity to manage 
social and/or economic risks, 53 and includes health insurance, 
food assistance, travel vouchers and cash transfers. 54 Cash 
transfers generally provide economic support to impoverished 
people with the aim of moving them out of extreme poverty 
and vulnerability while improving human capital. 55–60 
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 Fig 3.  Percentage of patients 
experiencing an adverse 
tuberculosis (TB) outcome 
analysed by poverty, education 
level, symptom duration, 
previous TB, catastrophic costs 
and resistance proﬁ le. Error 
bars represent 95% conﬁ dence 
intervals; p-values correspond to the 
association of each variable with 
adverse TB outcome in univariable 
logistic regression except for 
poverty and symptom duration 
that were analysed as continuous 
variables. In multivariable regression 
analysis, the following variables 
remained independently associated 
with adverse TB outcome: time 
too unwell to work (p=0.02), 
catastrophic costs (p=0.003), 
having had a previous episode 
of TB (p=0.004) and currently 
having multidrug resistant (MDR) 
TB (p<0.0001). Reproduced with 
permission from Wingﬁ eld  et al . 11 
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Following on from the phase 1 research, we hypothesised that 
defraying TB-related costs of TB-affected households using 
cash transfers could enhance access to TB preventive therapy, 
improve TB treatment outcomes, mitigate the effects of 
catastrophic costs and, potentially, control TB. 61 
 However, there was little operational evidence to 
guide implementation or evaluate the impact of TB-
related socio-economic support, including cash transfer 
interventions. 9,15,17,18 , 54–56 , 62–68 Building on the lessons learnt 
during the ISIAT project, 15 extensive expert and TB civil 
society consultation, 54 a systematic review of cash transfer 
interventions 55 and the phase 1 published research, 11 our 
IFHAD research group was funded by the Joint Global 
Health Trials (a consortium of Wellcome Trust, Medical 
Research Council and the UK Department for International 
Development) to undertake the Community Randomized 
Evaluation of a Socio-economic Intervention to Prevent 
TB (CRESIPT) project. The conception, design, and 
implementation of the complex TB-specific socio-economic 
intervention is described in more detail elsewhere. 31 Here, 
we report the economic and clinical effects of the household 
randomised controlled pilot evaluation of the intervention, 
which aimed to refine the intervention for the CRESIPT project 
while rigorously assessing the impact of the intervention on 
reducing catastrophic costs, improving access to TB preventive 
therapy and increasing TB cure and treatment success. 
 Methods 
 Intervention 
 The intervention aimed to increase screening for TB in 
household contacts and MDR TB testing in TB patients; 
adherence to TB treatment and preventive therapy and 
engagement with socio-economic support activities. The 
conceptual framework of the integrated intervention is shown 
in Fig  4 and comprised economic and social support: 
 >  Economic support consisted of conditional cash transfers 
throughout treatment to defray average household TB-relat-
ed costs thereby reducing TB risk factors while also incen-
tivising and enabling equitable access to care. Cash transfers 
were provided on completing each month of continued 
treatment, allowing a home visit from the project team, the 
household attending a participatory community meeting, 
and completion of treatment by the patient and preventive 
therapy by relevant contacts (Table  1 ).The cash transfers were 
designed so that if a patient achieved all possible conditions 
and thereby received all possible cash transfers throughout 
treatment, this would largely defray the direct out-of-pocket 
expenses for their entire illness that were previously found 
to be 10% of annual household income in this study site 
(US $230). Seven potential cash transfer scenarios are shown 
in  Fig 5. 
 >  Social support consisted of household visits and 
 participatory community meetings performed by the 
 CRESIPT research nurses and members of the local TB 
civil society, which aimed to provide information, mutual 
 support and empowerment, and stigma reduction. The 
household visits were made shortly after patients were start-
ed on treatment and focused on education concerning TB 
transmission, treatment, preventive therapy and domestic 
fi nances. The community meetings took place monthly in 
each study site community. 69 The meetings re- emphasised 
the educational themes of the household visit through 
interactive games and workshops, and developed an event 
entitled ‘TB Club’ in which participants shared TB-related 
and other life experiences within a mutually supportive 
group setting. 70 
 Participants 
 Any patient initiating treatment with the Peruvian national 
TB control programme was invited to participate between 10 
February and 14 August 2014. Patients were excluded if they 
were unable or unwilling to give written, informed consent. For 
patients who were minors, a parent or guardian was asked to 
give informed consent and patients who were old enough were 
also invited to provide their assent to participate. 
Control TB disease in the community and inform global TB policy
Find TB Find TB Cure TB Support families aﬀected by TB
Ai
m
Ac
v
i
es
O
ut
pu
ts
O
ut
co
m
es
Im
pa
ct
Economic support to reduce poverty-related TB risk factors, and incenvise and
enable TB treatment and prevenon 
Condional cash transfers on compleon of the naonal TB programme and CRESIPT project goals
Screening for
TB and MDR TB
Engaging with CRESIPT social support acvies
(household visits and community meengs)
for mutual support, sgma reducon
and empowerment
Adhering to TB treatment
and/or chemoprophylaxis
 Fig 4.  Conceptual framework of 
the tuberculosis-speciﬁ c 
socio-economic intervention. 
CRESIPT = Community 
Randomized Evaluation of a 
Socio-economic Intervention to 
Prevent TB; MDR = multidrug 
resistant; TB = tuberculosis. 
Reproduced with permission from 
Wingﬁ eld et al. 31 
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 Randomisation 
 Patient households were randomised (at a 1:1 ratio in restricted 
blocks of 30 per health centre according to predefined random 
number tables) to the control or intervention arm: 
 > control – TB-affected households in which a TB patient re-
ceived the Peruvian national TB control programme standard 
of care only 
 > intervention – TB-affected households in which a TB patient 
received the Peruvian national TB control programme stan-
dard of care plus the socio-economic intervention. 
 Preventive therapy 
 The most recent Peruvian TB programme guidelines that 
applied throughout this study recommended that preventive 
therapy be provided to all contacts under 5 years old of a patient 
with non-MDR pulmonary TB (unless the contact had had 
previous TB disease), and preventive therapy should also be 
considered for contacts aged 5–19 years of a patient who had a 
tuberculin positive skin test indicating latent TB infection and 
were a contact of a patient with non-MDR pulmonary TB. 71 
However, tuberculin was generally unavailable throughout this 
study, which meant that decisions regarding preventive therapy 
in contacts aged 5–19 years were predominantly based on 
clinical grounds alone (eg sputum smear positivity, time spent 
with index case) and thus heterogeneous across community 
health posts. Preventive therapy consisted of a 6-month course 
of daily isoniazid that was collected weekly from health posts by 
patients and taken unsupervised at their home. 71 
 Table 1.  Conditional cash transfer scheme 
 Double incentives 
Output Condition What the person with TB and their household members are 
required to do to receive a double incentive 
What each 
TB-affected family 
will receive in Soles 
Screening for TB 
and MDR TB
Patient: sputum 
sample
Give a sputum sample prior to starting treatment and complete the 
questionnaire with the research nurse. The national TB programme must 
have registered the person with TB in their health post's TB patient register.
40 ($14)
Contact: TB 
screening
All (100%) of the people registered as living in the same house as the 
person with TB attend their medical appointment or give a sputum 
sample (that has a result) to rule out TB. Those people who need to take 
medicine to prevent TB (chemoprophylaxis) or TB treatment must have 
started it. Contacts who do not need to take such treatment must be 
confirmed in the medical treatment cards.
150 ($54)
Adherence to 
TB treatment or 
chemoprophylaxis
Patient: adherence 
to treatment
 Sensitive/non-MDR patients (including those with HIV) during 
the first 50 doses of treatment:  each 25 does (approximately each 
month) of TB treatment taken, missing no more than 2 doses.
50 ($18)
 MDR patients (including those with HIV) during the first 150 
doses of treatment: each 25 doses (approximately each month) of TB 
treatment taken, missing no more than 2 doses.
50 ($18)
 Sensitive/non-MDR patients (including those with HIV) after the 
first 50 doses to the end of treatment: each 24 doses (approximately 
2 months) of TB treatment taken, missing no more than 1 dose.
50 ($18)
 MDR patients (including those with HIV) after the first 150 doses 
to the end of treatment: each 50 doses (approximately 2 months) of 
TB treatment taken, missing no more than 2 doses.
50 ($18)
Patient and 
contacts: completion 
of TB treatment and 
chemoprophylaxis
The person with TB completes their TB treatment and all (100%) of the 
people who live with them, who started chemoprophylaxis to prevent 
TB, finish their chemoprophylaxisis.
100 ($36)
Engage with 
CRESIPT social 
activities
Patient and 
contacts: home 
visit
In the first week following recruitment to the project, allow the CRESIPT 
team to visit the TB patient's house, complete the questionnaire (if 
necessary) and list all of the people who live in the same house as them.
50 ($18)
Patient and 
contacts: community 
meetings
By 3 months following recruitment, the person with TB and all (100%) 
of the people that the CRESIPT team listed as living in the same house 
as them attend at least one CRESIPT community meeting.
100 ($36)
Complete all conditions The person with TB and all of their contacts complete all of the above 
project conditions, including adhering to treatment for the duration of 
treatment.
640 ($230)
 CRESIPT = Community Randomized Evaluation of a Socio-economic Intervention to Prevent TB; MDR = multidrug resistant; TB = tuberculosis 
CMJv16n6S-Wingfield.indd   84 23/11/16   7:39 PM
Addressing the social determinants of TB
© Royal College of Physicians 2016. All rights reserved. s85
 Treatment 
 The Peruvian national TB control programme offered free 
TB diagnostic testing to all suspected TB patients who, once 
diagnosed, received free anti-TB directly observed therapy 
(DOT) administered at health posts. 71 TB treatment outcome 
data were collected collaboratively with the Peruvian national 
TB control programme from their treatment cards at the time 
of final follow-up and were not influenced by the research. 
Peruvian TB programme outcomes were consistent with those 
defined by the WHO. 72 
 The Peruvian TB programme define cure of drug-susceptible 
TB as a patient with bacteriologically confirmed TB at diagnosis 
who completes treatment and has a negative sputum smear 
during the final month of treatment. 71 This involved confirmation 
during clinical assessment by a national TB programme physician 
to evaluate symptoms, examination, weight trend and, when 
necessary, investigations such as chest radiographs and blood 
tests. Patients who completed their TB treatment course but 
did not complete the required sputum testing and/or physician 
review were classified as having completed treatment. Other 
programmatic outcomes were death (all-cause mortality during 
TB treatment), failure of treatment (as determined by the physician 
and/or demonstrated by positive sputum microscopy/culture after 
4 months of treatment), loss to follow-up and unknown outcome 
(patient relocated to another region and/or inability to determine 
outcome). The Peruvian TB programme defined treatment success 
as patients who completed treatment or were cured. 
 An additional project definition was ‘continuing on 
treatment’ after our 28-week follow-up interview. MDR TB 
patients, whose treatment duration commonly extends to 24 
months, were defined as continuing treatment if still taking 
TB treatment at this 28-week follow-up interview. This was 
also the case for patients with drug-sensitive TB and prolonged 
treatment courses either due to poor adherence (but not loss to 
follow-up) or based on clinical grounds. 
 Study outcomes 
 The primary study outcome was uptake of TB preventive 
therapy in contacts under 20 years of age in intervention 
households compared with control households. Completion of 
TB preventive therapy was operationally defined in line with 
Peruvian national guidance: contacts who started and took 
6 months (24 weeks) of preventive therapy (as documented in 
their preventive therapy treatment cards). 71 
 Secondary study outcome was the national TB control 
programme confirmed TB cure in patients as described above. 
This analysis evaluated patients with cure versus patients 
without cure without any exclusions (intention-to-treat); and 
Parcipant
Paent who declines
to parcipate
Paent who defaults
immediately
Paent who adheres,
completes and is cured
but does not engage
with social acvies
Paent who lives alone
and opmally achieves
all condions
Paent who lives with
partner and seven
children and opmally
completes all condions
Paent with HIV who
opmally completes
all condions
Paent with MDR TB
who opmally
completes all condions
Screening for TB
and MDR TB
Paent
× × × × × ×
 × × × × ×
    × ×
     
     
     
     
Contacts Paent Paent &contacts
Household
visit
Community
meeng
Adhering to
treatment
and/or
chemophrophylaxis
Engaging with
CRESIPT social
acvies
482
266
230
230
176
14
0
0 100
Total amount the paent would receive
in condional cash transfers (US $)
200 300 400 500
 Fig 5.  Cash transfer received by participants in seven different potential scenarios during intervention implementation. Typically, in Peru, 
treatment of TB in people with non-MDR TB has a duration of 6 months; in people with HIV TB co-infection, treatment lasts 9 months; and in people with 
MDR TB, treatment lasts 24 months. MDR = multidrug resistant; TB = tuberculosis. Reproduced with permission from Wingﬁ eld  et al . 31 
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treatment success (sum of completed treatment and confirmed 
cure) versus no treatment success without any exclusions 
(intention-to-treat). 73 
 Tertiary study outcome was TB-related costs defrayed 
and catastrophic costs mitigated calculated for intervention 
households and compared with control households (who did 
not receive any conditional cash transfers). 
 Feedback 
 At 24 weeks following treatment initiation, intervention 
household participants were asked to complete a mixed-
methods exit questionnaire to collect feedback on, and 
suggest improvements to, the social and economic support 
activities. 
 Analysis 
 Methods for collecting TB-related costs data replicated those 
used during phase 1 of the research. Data at the household and 
individual (patient or contact) level were used for intention-
to-treat and supplementary analyses with adjustments for 
household clustering using robust standard errors because 
there was more than one household contact per patient in 
most households. The primary and secondary outcome were 
analysed by univariate logistic regression and multiple logistic 
regression adjusted for household clustering and known 
confounders measured at baseline (including household-
level factors such as poverty, household crowding, head of 
household's highest education level, monthly income and 
food insecurity; and patient-level factors such as age, gender, 
employment status and TB resistance profile) that generated 
adjusted odds ratios (aOR) for relevant, contributory socio-
economic and health factors. Time-to-event analysis was 
performed in order to generate a crude, unadjusted log-rank 
value for difference between the number of weeks of preventive 
therapy taken by household contacts from intervention versus 
supported households. 
 Results 
 Participants 
 The recruitment period was from 10 February 2014 to 14 
August 2014 when the  a priori study sample size was reached 
and data collection on TB-affected household costs continued 
until 1 June 2015. Fig  6 shows TB-affected household 
recruitment and participation: 312 TB patients from separate 
households were invited to participate, of whom 90% 
(282/312) were recruited. Of these, 147 were randomised to the 
control arm and received normal standard of care only and 
135 were randomised to the intervention arm and additionally 
TB paents (n=312) and their
household contacts (n=1,331)
invited to parcipate
4 died prior to
compleng treatment
26 declined to
parcipate
TB paents (n=282) and their
household contacts (n=1,290),
of whom 518 were under 20 years
old, recruited
Randomisaon
Intervenon arm
TB paents (n=135) and their
household contacts (n=646), of
whom 260 were under 20 years
old, randomised to intervenon
arm*
3 paents did not
complete follow-up
3 paents had
TB diagnosis revoked
TB paents (n=147) and their
household contacts (n=644), of
whom 258 were under 20 years
old, randomised to control arm*
Household contacts under
20 years old (n=206) of TB
paents (n=132) who completed
ﬁnal follow-up**
Household contacts under
20 years old (n=204) of TB
paents (n=140) who completed
ﬁnal follow-up**
Control arm
54 contacts did not
complete follow-up
4 paents did not
complete follow-up
54 contacts did not
complete follow-up
 Fig 6.  Participant 
recruitment and 
randomisation. 
Recruitment 
constituted 
completing 
informed consent 
and a recruitment 
questionnaire. 
Dashed arrows refer 
to participants who 
were not included 
in the ﬁ nal analysis . 
*Secondary outcome 
analysis; **primary 
outcome analysis. 
Reproduced with 
permission from 
Wingﬁ eld T, Tovar 
MA, Huff D  et al . The 
economic effects 
of supporting 
tuberculosis-
affected households 
in Peru.  Eur Respir J 
2016;48:1396–410. 
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received the socio-economic intervention. 68% of patients 
had sputum smear-microscopy positive TB. 9% (24/282) 
of patients had MDR TB, none of whom had been cured or 
completed treatment during the study because, in Peru, MDR 
TB treatment generally requires at least 2 years of continuous 
antibiotic therapy tailored to individuals’ resistance profiles. 
No substantive baseline imbalances were found between 
intervention and control patients. Of the intervention TB-
affected households, 98% (132/135) completed final follow-up. 
Nevertheless, all 135 intervention TB-affected households 
had TB-related costs data available for analysis. Patients had 
an average of five contacts, 97% (1,290/1,331) of whom were 
recruited. 40% (518/1,290) of recruited contacts were under 
the age of 20 years; of these, 410 completed follow-up. 
 Conditional cash transfers 
 122/135 (90%) of intervention TB-affected households received 
at least one conditional cash transfer. These 122 intervention 
TB-affected households received a total of 890 conditional 
cash transfers (80% of potential conditional cash transfers), 
receiving on average a total of 520 Peruvian Soles (US $173), 
which is equivalent to 3.5% of average TB-affected household 
annual income or 42% of average TB-affected household 
monthly income. 31,74 
 Study outcomes 
 Contacts under 20 years of age from intervention households 
were more likely than those from control households to 
start preventive therapy (44% versus 26%, aOR 2.2 (95% CI 
1.1–4.2), p=0.022, Fig  7 ). Although crude analysis showed 
that household contacts were more likely to complete 3 
and 6 months of preventive therapy, these increases were 
not significant after adjusting for household clustering 
(completion of 3 months 33% versus 22%, aOR 1.8 (95% CI 
0.90–3.7), p=0.095 and completion of 6 months 20% versus 
12%, aOR 1.9 (95% CI 0.79–4.6), p=0.15, Fig  7 ). 
 The intention-to-treat-analysis showed that patients from 
intervention households were more likely than those from control 
households to have confirmed cure (51% (95% CI 43–60%) 
versus 37% (95% CI 30–45), aOR 1.8 (95% CI 1.1–2.9), p=0.02, 
Fig  8 ). In addition, patients from intervention households were 
more likely to have treatment success than patients from control 
households (64% versus 53%, aOR 1.8 (95%CI 1.1–2.9), p=0.02, 
Fig  8 ). 
 Overall, 36% of patient households incurred catastrophic 
costs. Compared with control households, intervention 
households were less likely to incur catastrophic costs (30% 
(95%CI 22–38) of intervention households versus 42% (95%CI 
34–50) of control households, p=0.002, Fig  9 ). 
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 Feedback 
 99 intervention households provided feedback. The proportion 
of those households rating the following socio-economic 
activities as good or excellent was: home visits 89/99 (90%), 
health-post visits 82/99 (83%), TB workshops 81/99 (82%), 
TB Clubs 79/99 (80%) and conditional cash transfers 83/99 
(84%). Participant feedback and suggested improvements are 
summarised in  Table 2. 
 Discussion 
 During the CRESIPT pilot study, we designed, implemented, 
refined 31 and evaluated a novel TB-specific socio-economic 
intervention, including cash transfers in a resource-constrained 
setting. The intervention proved to be acceptable and feasible, 69 
decreased the likelihood of incurring catastrophic costs, and 
increased TB preventive therapy uptake and adherence in 
contacts, and TB cure and treatment success in patients. 
 Despite more than one-third of the TB-affected households 
experiencing catastrophic costs and thus being at increased risk 
of adverse treatment outcome, 75 intervention households were 
less likely to incur catastrophic costs than control households. 
This finding is encouraging because it has the potential to 
contribute to the WHO's goal of eliminating catastrophic costs 
by 2020. During planning of the intervention, it had been 
estimated that, if implemented nationally, this conditional 
cash transfer programme would increase the Peruvian TB 
programme budget by approximately 15% per patient. 22 Focus 
group discussions with key stakeholders, including local staff 
of the Peruvian TB programme and a civil society of TB-
affected people, suggested that such an increase in programme 
expenditure was locally appropriate, affordable and potentially 
sustainable. 13,15 
 The finding that this intervention increased TB preventive 
therapy uptake and the number of weeks of preventive therapy 
taken is important because non-adherence to TB preventive 
therapy is frequent 32–35 , 46 , 76–80 and leads to higher rates of 
secondary TB. Nevertheless, it must be noted that despite a 
trend towards increased TB preventive therapy completion in 
the intervention contacts, this was not statistically significant 
and many contacts who were probably eligible for TB preventive 
therapy did not complete it despite being offered our socio-
economic intervention. A potential reason for this may be that 
conditional cash transfers for preventive therapy were not given 
monthly like they were for TB treatment and total cash transfers 
did not completely mitigate households’ TB-related costs. Other 
reasons include social activities not leading to lasting positive 
health-behaviour changes over the 6 months of required 
preventive therapy. 
 While our findings suggest that conditional cash transfers 
may contribute to improved patient outcomes (perhaps 
through diminishing food insecurity during TB treatment 
as well as improved access to medical care), it must be 
noted that the intervention went beyond cash transfers by 
offering education during household visits and participatory 
community meetings to inform and promote stigma reduction, 
inclusiveness and empowerment. This social support focused 
on risk factors for non-adherence to preventive therapy such as 
being female and/or belonging to a marginalised group, 43 , 81–83 
age, 83,84 illegal drug use, 46 homelessness, 47 alcohol misuse, 85 
and TB-affected families’ and individual's own knowledge, 
attitudes and perceptions. 80,86 Although our group had 
originally applied for funding to perform a 2×2 factorial study 
evaluating economic support versus social support and socio-
economic support versus standard of care, the sample size 
required was prohibitive and that application was not funded. 
The final funded study design of this CRESIPT pilot study 
did not allow analysis of the differential impact of the social 
support component and the economic support component 
of cash transfers on access to preventive therapy and TB 
cure rates. Nevertheless, in the field of HIV, conditional cash 
transfers interventions have often been complemented with 
health education for beneficiaries, and it has been suggested 
that, without education or social support, conditional cash 
transfers are unlikely to have an impact on health outcomes. 87 
 Table 2.  Summary of tuberculosis-affected households’ qualitative feedback. Feedback focused on positive 
aspects, aspects to improve on and suggested improvements of the social and economic elements of the intervention 
Intervention 
activity 
Positive Aspect to improve on Suggested improvement 
Social Improved information and 
education 
 Enhanced emotional and 
mutual support 
 Increased self-confidence 
and esteem 
 Motivating
Health-post, home visits, TB 
workshops and TB clubs too 
infrequent 
 Lack of forewarning and difficulty 
coordinating times of social activities 
 Workshops and clubs could be more 
dynamic
Increase health-post visits to at least weekly and 
home visits, TB workshops and clubs to twice a 
month 
 Earlier formal invitation to activities followed up 
by reminder phone call or text 
 Include better audiovisuals: especially music and 
videos (including patient testimonies)
Economic Enabled participants to buy 
better food and cover travel 
costs to health-post for 
directly observed therapy or 
contact screening 
 Cash transfers were 
encouraging and motivating
Transfers not punctual, too 
infrequent and not enough 
 Complications of bank transfers 
included difficulty withdrawing cash, 
wasted visits when cash was not yet 
deposited and hidden bank charges
Increase cash transfer amounts, allow maximum 
3-day wait to arrive and provide cash transfers 
twice a month 
 Inform household when cash transfers have 
arrived 
 Allow participants to save up cash transfers (eg 
have all transferred at one time)
 TB = tuberculosis 
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Thus, optimising social support, education and information, 
and addressing specific aspects of poverty – such as food 
insecurity, unemployment and housing – are likely to be key 
issues on which to focus in order to strengthen the impact of 
future interventions. 
 The findings of phase 2 of our research show that a novel, 
complex, socio-economic intervention was acceptable, feasible, 
reduced catastrophic costs, and increased TB preventive therapy 
uptake, confirmed TB cure and treatment success. Informed 
by these findings, the socio-economic intervention has been 
further refined in order to assess its impact on community TB 
control during CRESIPT. 
 Conclusions 
 In impoverished shantytowns of Callao, Peru, TB remains 
a social disease; despite TB treatment being ostensibly free, 
having TB disease was expensive for impoverished TB patients. 
The new definition of catastrophic costs created during the 
phase 1 of this research demonstrated that such costs are 
clinically relevant because they are associated with greater 
likelihood of adverse TB outcome. Indeed, catastrophic costs 
explained as many adverse outcomes as MDR TB. The novel 
catastrophic costs threshold defined by this research has since 
been endorsed by the WHO and become part of global TB 
control policy; informing implementation of the TB Patient 
Costs tool, which is being piloted in sentinel sites for potential 
scale-up from 2015 onwards. 
 Through multi-sectoral collaboration and supported by 
evidence from a systematic review, we designed a novel TB-
specific socio-economic intervention to improve access to 
preventive therapy, increase TB cure and mitigate catastrophic 
costs. The intervention was refined to better meet patient and 
household needs during implementation through community 
participation, engagement and acceptability feedback, and 
subsequently proved to be feasible, acceptable, reduced TB-
affected households’ catastrophic costs and improved TB care 
and prevention measures in a challenging, impoverished setting. 
This research emphasises the need for larger-scale integrated 
socio-economic interventions to improve TB control and also 
other health outcomes. In light of our findings and in conjunction 
with key stakeholders of the WHO and the World Bank, we 
have developed the protocol of the larger scale, adequately 
powered CRESIPT study, which will evaluate the impact of the 
intervention on TB prevalence and control in the study setting. 
 Despite the positive findings of this research, the impact of 
the socio-economic intervention may have been limited by the 
modest defraying of TB-related and catastrophic costs achieved 
through conditional cash transfers. Such a modest yet significant 
impact means that, in its current form, the intervention may be 
unlikely to markedly decrease community rates of incident and 
prevalent TB during the larger-scale CRESIPT project. Therefore, 
through liaison with international policymakers in the WHO's 
Task Force on Catastrophic Costs and Task Force on Social 
Protection, the intervention has been refined for implementation 
during the CRESIPT study. Refinements include increasing the 
frequency and amounts of conditional cash transfers in order 
to fully mitigate catastrophic costs, provide conditional cash 
transfers for individual members of the TB-affected household 
(including monthly transfers to individual household contacts 
for adherence to preventive therapy) and strengthen the highly 
valued social support provided by the intervention – especially 
for high-risk patients such as the homeless, those with drug 
addiction and those with MDR TB. In this way, the IFHAD team 
hopes to optimise the CRESIPT project's impact on TB-related 
costs mitigation, to enhance socio-economic support and, hence, 
improve TB control. 
 This research characterised the social determinants of TB, 
including TB-related catastrophic costs, in Peruvian shantytowns 
and subsequently created, implemented and refined an 
innovative TB-specific socio-economic intervention to mitigate 
catastrophic costs and support TB-affected households. The 
intervention is now ready for further impact assessment at a 
community level. The findings of CRESIPT, an extension of this 
research, will aim to assist TB control programmes to effectively 
implement the recent – yet 150 years overdue – global policy 
change of providing socio-economic support to control TB. ■ 
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